Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Philippe Moreau, MD; Suzanne Lentzsch, MD, PhD; and Shaji Kumar, MD, discuss therapeutic innovations in the treatment of multiple myeloma, including frontline quadruplet therapy, administration considerations for therapy, and optimal sequencing of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate recent efficacy and safety data from pivotal trials assessing new and emerging therapies for MM
• Apply disease-specific and individual patient considerations to optimize personalized treatment planning in MM
• Assess the evolving evidence on using MRD assessments to guide the choice and duration of maintenance therapy
• Implement the latest best practices for preventing and managing treatment-related toxicities in patients with MM

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Sanofi.

Chair:

Mohamad Mohty, MD, PhD

Professor of Hematology, Sorbonne University
Head, Clinical Hematology and Cellular Therapy Department
Saint-Antoine Hospital
Paris, France

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Stemline Therapeutics, Takeda; Speakers Bureau: Janssen, Jazz Pharmaceuticals, Pfizer, Sanofi; Grant/Research Funding (to institution): Bristol Myers Squibb, Janssen, Pfizer, Sanofi

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, MN

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Arcellx, BD Biosciences, BeiGene, Bristol Myers Squibb, CVS Caremark, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanofi, Siemens; Grant/Research Funding (to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, Gracell Biotechnologies, GSK, Janssen, Oricell Therapeutics, Roche-Genentech, Sanofi, Takeda, TeloGenomics

Suzanne Lentzsch, MD, PhD

Professor of Medicine
Columbia University
Director, Multiple Myeloma and Amyloidosis Program
Columbia University Irving Medical Center
New York, NY

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Alexion, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Karyopharm, Pfizer, Regeneron, Sanofi; Grant/Research Funding (to institution): Sanofi; Royalty or Patent Benefits: Anselamimab

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes, France
Nantes, France

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Amgen, Bristol Myers Squibb, Janssen, Pfizer, Sanofi, Takeda

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on future directions in MM and audience Q&A, go to https://www.gotoper.com/courses/medical-crossfire-turning-therapeutic-innovation-into-practicepersonalizing-care-in-multiple-myeloma-p2f5.

Release Date

June 30, 2026

Expiration Date

June 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.